Jazz Pharmaceuticals plc (JAZZ)

NMS – Real vaqt narxi. Valyuta: USD

250.30

+2.33 (0.94%)

Bozor ochiq: Aug 12, 2026, 3:08 PM EDT

248.05

+0.07 (0.03%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

12.08.2026

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating.

11.08.2026

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million. Deal centers around Actio's lead drug for KCNT+ epilepsy, ABS-1230.

10.08.2026

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

10.08.2026

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at up to $1.32 billion, adding an experimental treatment for ‌a rare inherited form of epilepsy that has no approved therapies.

10.08.2026

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment DUBLIN and SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration. Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule precision therapy KCNT1 ion channel inhibitor.

07.08.2026

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

06.08.2026

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

Videolar

No Data

There is no data to display

Press-relizlar

10.08.2026

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

03.08.2026

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company raises 2026 revenue guidance – – Prepared to launch Ziihera® in HER2+ 1L GEA immediately following FDA approval – – Xywav® revenues grew 13% YoY with 525 net patient adds in 2Q26 – – Epidiolex® revenues grew 16% YoY – DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026. "Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals plc (JAZZ)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Videolar

No Data

Press-relizlar

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Videolar

No Data

Press-relizlar

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Search stocks

Jazz Pharmaceuticals plc (JAZZ)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Videolar

No Data

Press-relizlar

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Videolar

No Data

Press-relizlar

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results